Clinical Trial Update: Pravastatin Reduces Acute Phase Response of Zoledronic Acid [Phase 4]

View source ↗

Summary

Phase 4 trial investigating whether pravastatin reduces the acute phase response associated with zoledronic acid in postmenopausal osteoporosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postmenopausal Osteoporosis

Drugs mentioned

• Pravastatin (pravastatin)
• Zoledronic acid (Zoledronic acid)

Snippet

Sponsor: Peking University Third Hospital | Conditions: Postmenopausal Osteoporosis | Phase 4 | Status: UNKNOWN